Your browser doesn't support javascript.
loading
Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial.
Hara, Chikako; Kamei, Motohiro; Sakaguchi, Hirokazu; Matsumura, Nagakazu; Sakimoto, Susumu; Suzuki, Mihoko; Nishida, Kentaro; Fukushima, Yoko; Nishida, Kohji.
Afiliación
  • Hara C; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Kamei M; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan. motokamei@gmail.com.
  • Sakaguchi H; Department of Ophthalmology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1103, Japan. motokamei@gmail.com.
  • Matsumura N; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Sakimoto S; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Suzuki M; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Nishida K; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Fukushima Y; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Nishida K; Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
Graefes Arch Clin Exp Ophthalmol ; 259(10): 2919-2927, 2021 Oct.
Article en En | MEDLINE | ID: mdl-33893866
ABSTRACT

PURPOSE:

Our previous 1-year pilot study evaluated the efficacy of intravitreally injected activated protein C (APC) in 10 eyes with ischemic central retinal vein occlusion (CRVO). The reperfusion of the areas of retinal nonperfusion (RNP) exceeded 50% of the baseline in five (50%) eyes 1 year after the APC injection. The current study evaluated the long-term efficacy and safety of intravitreal APC.

METHODS:

The 10 eyes in the pilot study were included in this study. Other treatments were administered at the physicians' discretion after the pilot study. We evaluated visual acuity (VA), central retinal thickness (CRT) and perfusion status, and adverse events and severity over the long term.

RESULTS:

The median follow-up was 60 months (range, 48-68 months). Compared with baseline, the post-treatment VA improved significantly (P < 0.001) from 1.39 to 1.06 logarithm of the minimum angle of resolution. The CRT improved significantly (P < 0.001) from 1090 to 195 µm at the last visit. The RNP areas decreased from an average 29.7 disc areas (DAs) at baseline to an average 16.5 DAs at the last examination (mean, 40 ± 6.5 months after the first APC treatment). No adverse events were related to intravitreal APC.

CONCLUSION:

No complications were associated with intravitreal APC, the clinical course improved, and improved RNP was maintained for the long term, suggesting that intravitreal APC may be an alternative treatment for CRVO.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Oclusión de la Vena Retiniana / Edema Macular Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Graefes Arch Clin Exp Ophthalmol Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Oclusión de la Vena Retiniana / Edema Macular Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Graefes Arch Clin Exp Ophthalmol Año: 2021 Tipo del documento: Article País de afiliación: Japón